新冠疫情期间系统性风湿病患者药物调整的患者视角
该研究对纽约学术中心13名风湿科医生的112例成人系统性风湿病患者进行电话访谈,了解疫情期间用药调整情况。患者报告了七类药物调整模式,部分调整虽不利于疾病控制,但旨在降低感染风险或应对无法获取实验室检查和体格检查的困境。
要点
- 患者因担心SARS-CoV-2感染而调整或停用免疫抑制药物,部分调整不利于疾病控制。
- 调整模式包括羟氯喹角色、糖皮质激素使用、推迟输注及感染后用药计划等七类。
- 当面就诊停止导致无法获取实验室检查和体格检查,促使患者采取临时性偏离计划的用药措施。
核心结论
- 疫情期间系统性风湿病患者进行了大量药物调整,部分为临时性措施并偏离了计划方案。
研究设计与样本
- 对13名风湿科医生的112例成人系统性风湿病患者进行电话访谈和开放式提问,采用内容与主题分析生成药物调整类别。
主要发现
- 患者平均年龄50岁,86%为女性,34%为非白人种族或拉丁裔,30%为狼疮、26%为类风湿关节炎、44%为其他诊断。
- 患者报告了七类药物调整模式:药物与SARS-CoV-2感染风险增减、羟氯喹角色、维持用药现状、糖皮质激素角色、根据临床疾病活动增减现有药物、推迟输注、感染SARS-CoV-2后的用药计划。
- 部分调整虽不利于疾病控制,但旨在降低感染风险并在无法获取实验室检查和体格检查时尽量减少潜在伤害。
临床怎么用
- 临床医生应关注患者因感染担忧而自行调整免疫抑制药物的情况,并评估其对疾病控制的影响。
- 在面诊受限时需主动询问患者用药计划及获取实验室检查的困难,避免不适当的临时性药物调整。
局限性
- 研究仅纳入单一学术中心13名风湿科医生的患者,结果为患者自我报告,未评估药物调整的短期和长期后遗症。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Concerns about severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection may have led to changes or discontinuation of immunosuppressive medications among patients with systemic rheumatic disease. Our goal was to assess patients' perspectives regarding medication modifications and deviations from planned uses during the height of the pandemic. METHODS: Adult patients of 13 rheumatologists at an academic center with physician-diagnosed rheumatic disease and prescribed disease-modifying medications were interviewed by telephone and asked open-ended questions about the impact of SARS-CoV-2 on their medications. Responses were analyzed using content and thematic analyses to generate categories that described patterns of medication modification. RESULTS: A total of 112 patients (mean age 50 years, 86% women, 34% non-White race or Latino ethnicity) with diverse diagnoses (30% lupus, 26% rheumatoid arthritis, 44% other) who were taking various medications were enrolled. Patients reported clinically relevant issues that were iteratively reviewed to generate unique categories of medication modification: medications and increased or decreased risk of SARS-CoV-2 infection; role of hydroxychloroquine; maintaining medication status quo; role of glucocorticoids; increasing or decreasing existing medications in relation to clinical disease activity; postponing infusions; and medication plan if infected by SARS-CoV-2. Some modifications were suboptimal for disease control but were made to mitigate infection risk and to minimize potential harm when patients were unable to obtain laboratory tests and physical examinations due to cessation of in-person office visits. CONCLUSION: During the height of the pandemic, substantial medication modifications were made that, in some cases, were temporizing measures and deviations from planned regimens. Future studies will assess short- and long-term sequelae of these medication modifications.
引用
- Mancuso CA, Duculan R, Jannat-Khah D, et al. Modifications in Systemic Rheumatic Disease Medications: Patients' Perspectives During the Height of the COVID-19 Pandemic in New York City. Arthritis Care Res (Hoboken). 2021. PMID: 33085850. doi:10.1002/acr.24489
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。